痴呆语言特点及及美金刚的有效治疗彭丹涛__培训课件.ppt

* The Alzheimer‘s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) is an 11 item scale assessing cognitive domains of memory, language, orientation, reasoning, and praxis. The scores range from 0 to 70 with lower scores indicating less impairment. This slide depicts the mean change in ADAS-cog (? SEM) score from baseline over 24 weeks of treatment with either memantine (20mg/day) or placebo.The data analysis is based on the observed cases (OC). Additionally the endpoint was also analyzed based on the intent-to-treat (ITT) population using the last observation carried forward (LOCF) method. Patients treated with memantine showed an improvement relative to baseline from week 4 to 18 (all p values ? 0.05), while patients receiving placebo exhibited progressive cognitive decline over the same study period. Significant benefit of memantine compared to placebo was observed at week 8 and was maintained to the study endpoint (LOCF analysis). The lack of statistical significance at week 24 for the ADAS-cog in the OC analysis could be due to attrition from the study of memantine-treated patients who were predominantly improving and of placebo-treated patients who were generally deteriorating. It is important to mention that the decline in ADAS-cog performance of the placebo group over the 24 week course of the study was less than that expected based on the natural history of the disease and compared to the performance of placebo groups in the majority of the clinical studies with AChE-Is in mild to moderate AD. * The Alzheimer‘s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) is an 11 item scale assessing cognitive domains of memory, language, orientation, reasoning, and praxis. The scores range from 0 to 70 with lower scores indicating less impairment. This slide depicts the mean change in ADAS-cog (? SEM) score from baseline over 24 weeks of treatment with either memantine (20mg/day) or placebo.The data analysis is based on the observed cases (OC). Additional